Destiny Pharma: Major US hospital-based clinical trial highlights benefit of nasal decolonization to reduce ICU infections caused by Staphylococcus aureus

Major US hospital-based clinical trial highlights benefit of nasal decolonization to reduce ICU infections caused by Staphylococcus aureus

Strong support for potential of XF-73 nasal product
as alternative to mupirocin

Brighton, United Kingdom – 18 October 2021 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, notes the important study report presented at the leading international conference, IDWeek virtual meeting which took place on 30 September – 3 October 2021.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH